🔴 Tenax Therapeutics is trading 7.2% down today with no clear new company-specific catalyst

Tenax Therapeutics is trading at $1.70, down 7.21%, with no clear new company-specific catalyst identified for October 13.

• XBI fell 2.01% during the regular session, providing sector context but not a confirmed explanation for the larger decline.
• On October 12, the company reported that its Phase 3 LEVEL trial of TNX-103 missed its primary and key secondary endpoints. The news drove a sharp selloff, but available reporting does not establish it as the direct cause of the October 13 move.